NLRP3 and COVID-19: This work thereby identifies a molecular mechanism by which SARS-CoV-2 infection causes ARDS, provides evidence that links the NLRP3 inflammasome and lung injury, and suggests that MCC950 and Ac-YVAD-cmk might function as potential therapeutic agents for the prevention and treatment of COVID-19.